Literature DB >> 2047875

Vaccinia virus: a tool for research and vaccine development.

B Moss1.   

Abstract

Vaccinia virus is no longer needed for smallpox immunization, but now serves as a useful vector for expressing genes within the cytoplasm of eukaryotic cells. As a research tool, recombinant vaccinia viruses are used to synthesize biologically active proteins and analyze structure-function relations, determine the targets of humoral- and cell-mediated immunity, and investigate the immune responses needed for protection against specific infectious diseases. When more data on safety and efficacy are available, recombinant vaccinia and related poxviruses may be candidates for live vaccines and for cancer immunotherapy.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2047875     DOI： 10.1126/science.2047875

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  104 in total

Review 1.  Overview of vector design for mammalian gene expression.

Authors:  R J Kaufman
Journal:  Mol Biotechnol       Date:  2000-10       Impact factor: 2.695

2.  Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Authors:  P S Polacino; V Stallard; J E Klaniecki; S Pennathur; D C Montefiori; A J Langlois; B A Richardson; W R Morton; R E Benveniste; S L Hu
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

4.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

5.  Activation of the human immunodeficiency virus type 1 long terminal repeat by vaccinia virus.

Authors:  K A Stellrecht; K Sperber; B G Pogo
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 6.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

7.  A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.

Authors:  Xianghong Chen; Fanqi Bai; Lubomir Sokol; Junmin Zhou; Amy Ren; Jeffrey S Painter; Jinhong Liu; David A Sallman; Y Ann Chen; Jeffrey A Yoder; Julie Y Djeu; Thomas P Loughran; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

8.  The 35-kilodalton protein gene (p35) of Autographa californica nuclear polyhedrosis virus and the neomycin resistance gene provide dominant selection of recombinant baculoviruses.

Authors:  R A Lerch; P D Friesen
Journal:  Nucleic Acids Res       Date:  1993-04-25       Impact factor: 16.971

9.  Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.

Authors:  R L Roper; L G Payne; B Moss
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.